27 min listen
Battling Resistance in Tumors with “Pan-Variant” Kinase Inhibitors
FromThe Bio Report
ratings:
Length:
30 minutes
Released:
Jun 2, 2022
Format:
Podcast episode
Description
The emergence of tyrosine kinase inhibitors represented a major advance in the fight against cancer, but the ability of tumors to mutate and develop resistance to these therapies remains a challenge. Theseus Pharmaceuticals is developing what it calls “pan-variant” kinase inhibitors in the hopes of outsmarting tumors by anticipating the range of kinases that may drive their spread and growth as they change. We spoke to Tim Clackson, president and CEO of Theseus Pharmaceuticals, about its structural-based approach to drug development, how it determines the appropriate targets for its pan-variant kinase inhibitors, and why it believes its next-generation TKIs can overcome the challenge of drug resistance.
Released:
Jun 2, 2022
Format:
Podcast episode
Titles in the series (100)
Remembering Industry Pioneer Ron Cape by The Bio Report